Liminal Biosciences is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis. The company is advancing promising research in small molecules for a range of diseases related to fibrosis including respiratory, liver and renal diseases. Through a separate business unit called Prometic, the company also focuses on the use of bioseparation technologies to isolate and purify biopharmaceuticals derived from human plasma. See our social media community guidelines at https://liminalbiosciences.com/social-media-community-guidelines/
Location: Canada, Laval
Member count: 201-500
Total raised: $105M
Founded date: 1994

Investors 3

Funding Rounds 1

DateSeriesAmountInvestorsDeal News

Mentions in press and media 2

09.08.2021Liminal Bi...LAVAL, QC and CAMBRIDGE, Engla...--marketscre...
05.05.2021LIMINAL BI...Notice of Annual and Special M...--marketscre...